FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
Evidence for efficacy is based on the results from the Study 1620
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular Lymphomas
During treatment with umbralisib, prophylaxis is recommended for Pneumocystis jirovecii pneumonia and to consider prophylactic antivirals to prevent CMV infection, including CMV reactivation
Breast Cancer Risk Genes
Two large case–control studies provide important information on the risk of breast cancer and cancer types that is associated with several genes and their variants
Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides Targeted Therapy Information
The ESMO ESCAT classification can be used to guide in the selection of patients with head and neck squamous cell carcinoma for targeted treatment strategies in clinical studies
EMA Recommends Extension of Indications for Pembrolizumab
Extension concerns the treatment of classical Hodgkin lymphoma
FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
Efficacy was demonstrated in the VISION study
Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab
Application concerned the use in combination with platinum-based therapy in previously untreated metastatic urothelial cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor
It is intended for the treatment of relapsed and refractory multiple myeloma
Majority of Patients With Cancer Are Willing To Be Vaccinated Against COVID-19
Results from a cross-sectional survey in France
EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
It is intended for second-line treatment of advanced cholangiocarcinoma with a FGFR2 fusion or rearrangement
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the CHECKMATE-9ER study
FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed Light Chain Amyloidosis
Evidence for efficacy is based on the results from the ANDROMEDA study